Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its underwritten public offering of 5 million shares of common stock at $20.00 per share, expected to generate gross proceeds of approximately $100 million. The company also granted underwriters a 30-day option to purchase up to an additional 750,000 shares at the same price, less underwriting discounts and commissions. The offering is anticipated to close on or about July 1, 2026, subject to customary closing conditions. Cantor is serving as sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners acting as co-managers.
Nuvectis plans to use the net proceeds to advance the development of its key programs: NXP100, NXP200, and NXP900. NXP100 is a late-stage Factor B inhibitor with best-in-class potential for treating complement-mediated diseases, offering a once-daily oral treatment option for conditions requiring lifelong therapy. NXP900 is an oral small molecule inhibitor targeting the SRC Family of Kinases, including SRC and YES1, designed to inhibit both catalytic and scaffolding functions for comprehensive signaling pathway shutdown. NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors, including central nervous system cancers, colorectal cancer, melanoma, and non-small cell lung cancer. The company also intends to support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes.
The significance of this offering lies in its potential to accelerate the clinical development of Nuvectis's pipeline, addressing unmet medical needs in immune complement-related conditions and oncology. With over $100 million in gross proceeds, the company is well-positioned to advance its programs through clinical trials, potentially bringing innovative therapies to patients. The involvement of multiple underwriters, including Cantor and H.C. Wainwright, underscores institutional confidence in Nuvectis's strategy. For more details, the full press release is available at https://ibn.fm/SrZnr.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100 as a complement Factor B inhibitor, NXP900 targeting SRC kinases, and NXP200 as a BRAF inhibitor. The company's approach aims to provide effective treatment options with convenience advantages, such as once-daily oral dosing. Additional information can be found at https://nuvectis.com/.
